Abstract
Reasons for infliximab failure in Crohn's disease and ulcerative colitis are debated. Serum levels of infliximab and anti-infliximab antibodies have been associated with loss of response. We aimed at determining cut-off levels for infliximab and anti-infliximab antibody concentrations associated with clinical response to infliximab maintenance therapy.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Scandinavian Journal of Gastroenterology |
Vol/bind | 46 |
Udgave nummer | 3 |
Sider (fra-til) | 310-8 |
Antal sider | 9 |
ISSN | 0036-5521 |
DOI | |
Status | Udgivet - 1 mar. 2011 |